Addressing clinical safety of antimicrobial resistance: personal perspectives

References

• D’Costa VM, King CE, Kalan L, et al. Antibiotic resistance is ancient. Nature. 2011;477(7365):457–461.
   PubMed Web of Science ®Google Scholar
• Paterson DL. “Collateral damage” from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(Suppl 4):S341–345.
   PubMedGoogle Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Sader HS, Castanheira M, et al. Distribution of main gram-positive pathogens causing bloodstream infections in United States and European hospitals during the SENTRY antimicrobial surveillance program (2010–2016): concomitant analysis of oritavancin in vitro activity. J Chemother. 2018;30(5):280–289.
   PubMed Web of Science ®Google Scholar
• Tackling drug-resistant infections globally. The review on antimicrobial resistance. 2016. Chaired by O'Neill J. Available from: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf
   Google Scholar
• de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLoS Med. 2016;13(11):e1002184.
   PubMed Web of Science ®Google Scholar
• Giske CG, Monnet DL, Cars O, et al. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother. 2008;52(3):813–821.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Matthaiou DK, et al. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents. 2008;32(5):450–454.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Kasiakou SK, Rafailidis PI, et al. Comparison of mortality of patients with Acinetobacter baumannii bacteraemia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother. 2006;57(6):1251–1254.
   PubMed Web of Science ®Google Scholar
• WHO. Antimicrobial resistance. Global report on Surveillance; 2014.
   Google Scholar
• WHO. Global action plan on antimicrobial resistance. 2015; [cited 2019 Aug 1]. Available from: https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1
   Google Scholar
• Zilberberg MD, Nathanson BH, Sulham K, et al. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017;17(1):279.
   PubMedGoogle Scholar
• Methé BA, Nelson KE, Pop M, et al. A framework for human microbiome research. Nature. 2012;486(7402):215–221.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Reinert RR, Cornely O, et al. Molecular relationships and antimicrobial susceptibilities of viridans group streptococci isolated from blood of neutropenic cancer patients. J Clin Microbiol. 1999;37(6):1876–1880.
   PubMed Web of Science ®Google Scholar
• Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017;10:CD007498.
   PubMedGoogle Scholar
• Rubinstein E, Keynan Y. Vancomycin revisited – 60 years later. Front Public Health. 2014;2:217.
   PubMedGoogle Scholar
• Fernandez L, Breidenstein EB, Hancock RE. Creeping baselines and adaptive resistance to antibiotics. Drug Resist Updat. 2011;14(1):1–21.
   PubMed Web of Science ®Google Scholar
• Jean SS, Lee WS, Bai KJ, et al. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009. Diagn Microbiol Infect Dis. 2015;81(4):290–295.
   PubMed Web of Science ®Google Scholar
• Services USDoHaH. 2013. ANTIBIOTIC RESISTANCE THREATS in the United States; p. 28. [cited 2019 Aug 1]. Available from: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf
   Google Scholar
• Harbarth S, Theuretzbacher U, Hackett J. Antibiotic research and development: business as usual? J Antimicrob Chemother. 2015;70(6):1604–1607.
   PubMed Web of Science ®Google Scholar
• Davies J, Davies D. Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev. 2010;74(3):417–433.
   PubMed Web of Science ®Google Scholar
• Blair JM, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42–51.
   PubMed Web of Science ®Google Scholar
• Ruppe E, Woerther PL, Barbier F. Mechanisms of antimicrobial resistance in gram-negative bacilli. Ann Intensive Care. 2015;5(1):61.
   PubMed Web of Science ®Google Scholar
• Hall CW, Mah TF. Molecular mechanisms of biofilm-based antibiotic resistance and tolerance in pathogenic bacteria. FEMS Microbiol Rev. 2017;41(3):276–301.
   PubMed Web of Science ®Google Scholar
• Lubbert C, Baars C, Dayakar A, et al. Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens. Infection. 2017;45(4):479–491.
   PubMed Web of Science ®Google Scholar
• America I. The 10 x ‘20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis. 2010;50(8):1081–1083.
   PubMed Web of Science ®Google Scholar
• Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents. 2010;35(2):194–199.
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16(2):184–186.
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108–2113.
   PubMed Web of Science ®Google Scholar
• Korbila IP, Michalopoulos A, Rafailidis PI, et al. Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study. Clin Microbiol Infect. 2010;16(8):1230–1236.
   PubMed Web of Science ®Google Scholar
• Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168.
   PubMed Web of Science ®Google Scholar
• Matthaiou DK, Michalopoulos A, Rafailidis PI, et al. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study. Crit Care Med. 2008;36(3):807–811.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734.
   PubMed Web of Science ®Google Scholar
• Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376(22):2134–2146.
   PubMed Web of Science ®Google Scholar
• Spellberg B, Gilbert DN. The future of antibiotics and resistance: a tribute to a career of leadership by John Bartlett. Clin Infect Dis. 2014;59(Suppl 2):S71–75.
   PubMedGoogle Scholar
• Tillotson G. Antimicrobial resistance: what’s needed. Lancet Infect Dis. 2015;15(7):758–760.
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Kakisi OK, Vardakas K, et al. Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer. 2007;109(11):2182–2189.
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377(2):122–131.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56–93.
   PubMed Web of Science ®Google Scholar
• Rafailidis PI, Pitsounis AI, Falagas ME. Meta-analyses on the optimization of the duration of antimicrobial treatment for various infections. Infect Dis Clin North Am. 2009;23(2):269–276. Table of Contents.
   PubMed Web of Science ®Google Scholar